Cover Image
市場調查報告書

胰外分泌不全:全球產業分析、市場趨勢、市場規模及市場佔有率的變化與預測

Exocrine Pancreatic Insufficiency Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2013 - 2023

出版商 Transparency Market Research 商品編碼 359764
出版日期 內容資訊 英文 71 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
胰外分泌不全:全球產業分析、市場趨勢、市場規模及市場佔有率的變化與預測 Exocrine Pancreatic Insufficiency Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2013 - 2023
出版日期: 2016年05月17日 內容資訊: 英文 71 Pages
簡介

本報告提供全球胰外分泌不全的市場調查,疾病及治療藥、診斷檢驗概要,影響市場成長因素分析,開發平台趨勢,藥物及診斷檢驗的收益規模的變化與預測,各地區、主要國家趨勢,競爭環境,以及主要企業的簡介等彙整。

第1章 序論

第2章 摘要整理

第3章 產業分析

  • 簡介、市場定義
  • 藥物療法之外的治療方法
  • 市場動態
  • 市場魅力度分析:各地區
  • 影響分析
  • 開發平台分析 (第II、I相)
  • 競爭分析

第4章 市場分析、預測:各藥物種類

  • 概要
  • 胰消化酵素補充藥
    • Creon
    • Zenpep
    • Pancreaze
    • Ultresa
    • Viokace
    • Pertzye
  • 開發平台分析、預測
    • Sollpura (Liprotamase)

第5章 市場分析:各診斷檢查

  • 概要
  • 血液檢驗
  • 超音波內視鏡檢驗 (EUS)
  • MRI
  • CT掃描

第6章 地區分析

  • 北美
    • 美國
    • 加拿大
    • 其他
  • 歐洲
    • 英國
    • 德國
    • 其他
  • 亞太地區
    • 中國
    • 日本
    • 其他
  • 南美
    • 巴西
    • 墨西哥
    • 其他
  • 其他
    • 南非
    • 俄羅斯
    • 其他

第7章 企業簡介

  • Abbvie Inc.
  • Allergan plc.
  • Nordmark Arzneimittel GmbH & Co. KG
  • Digestive Care, Inc.
  • Cilian AG
  • Anthera Pharmaceuticals Inc.
  • Janssen Pharmaceuticals Inc.
  • AzurRx BioPharma, Inc.

圖表

目錄

Exocrine pancreatic insufficiency (EPI) is a condition characterized by deficiency of the exocrine pancreatic enzymes, resulting in the inability to digest food properly, or a condition called maldigestion. These enzymes primarily consist of lipases for fat digestion, proteases for protein digestion, and amylases for starch digestion. Management of EPI is based primarily on pancreatic enzyme replacement therapy (PERT), but could also include lifestyle modifications and vitamin supplementation as appropriate. Increase in prevalence of diabetes and rise in prevalence of cystic fibrosis and chronic pancreatitis accentuates the demand for exocrine pancreatic insufficiency market worldwide. The most effective treatment for exocrine pancreatic insufficiency is to successfully treat the underlying condition causing the enzyme insufficiency. Chronic pancreatitis is a benign disease often characterized by recurrent episodes of abdominal pain supplemented by progressive pancreatic exocrine and endocrine insufficiency. Treatment with antioxidants may improve quality of life and reduce pain in patients suffering from chronic pancreatitis.

This research study analyzes the market for exocrine pancreatic insufficiency (EPI) in terms of revenue (US$ Mn). The exocrine pancreatic insufficiency (EPI) market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments of the market. The report also includes key market dynamics, such as drivers, restraints, and opportunities, affecting the demand for exocrine pancreatic insufficiency (EPI) treatment products globally. Comparative analysis has also been included in the executive summary that resembles the percentage market share of each regions in 2014 and 2023 respectively.

This report provides in-depth analysis of the exocrine pancreatic insufficiency market. The stakeholders for this report include companies involved in the manufacturing of products used in treatment of exocrine pancreatic insufficiency. For providing a snapshot of this market to the stakeholders, executive summary section is included in this report, which summarizes the market size, trends and competition in different regions.

The market overview section of this report analyzes market dynamics such as drivers, restraints and opportunities that influence the exocrine pancreatic insufficiency market in the current and future scenario. Market share analysis among the market players is analyzed to signify percentage share of the major players operating in the exocrine pancreatic insufficiency market. All these factors will help the market players to decide about the business strategies and plans to be incurred in future for strengthening their position in the global market.

The exocrine pancreatic insufficiency market by therapeutic has been segmented as pancreatic enzyme replacement therapy (PERT) drugs and diagnostic tests. PERT drugs involves Creon, Zenpep, Pancreaze, Ultresa and Pertzye. The diagnostic tests involves blood tests, endoscopic ultra-sonography, magnetic resonance imaging and CT scanning.

Geography wise, the exocrine pancreatic insufficiency market has been differentiated into five major regions: North America, Asia Pacific, Europe, Latin America and Rest of the World. Moreover, analysis for the major countries comprising U.S. Canada, Germany, U.K., Japan China, Russia, Brazil, Mexico and South Africa have also been provided in the report. A detailed qualitative analysis of the factors responsible for driving and restraining the growth of the exocrine pancreatic insufficiency market in various regions has been provided in this section.

The report provides market estimation of exocrine pancreatic insufficiency market in terms of revenue (US$ Mn) for all the segments and sub segments with CAGR % for period 2015 to 2023, considering 2014 as the base year. Furthermore, the report incorporates market attractiveness analysis by geography that depicts the most attractive and significant region in the global market in 2014.

The report concludes with the company profile section which includes company overview, financial overview, product portfolio, business strategies and recent developments for market players. The major players that are profiled in the report include Abbvie, Inc., Allergan plc, Digestive Carew, Inc., Cilian AG, Anthera Pharmaceuticals, Inc. and AzuRx Biopharma, Inc. are among others.

The global exocrine pancreatic insufficiency market is segmented into the following categories:

Global Exocrine Pancreatic Insufficiency Market, by Therapeutics

  • Pancreatic Enzyme Replacement Therapy (PERT) Drugs
    • Creon
    • Zenpep
    • Pancreaze
    • Ultresa
    • Viokace
    • Pertzye
  • Exocrine Pancreatic Insufficiency Drugs, Pipeline Analysis, Sollpura (Liprotamase)

Global Exocrine Pancreatic Insufficiency Market, by Diagnostic Tests

  • Blood Tests
  • Endoscopic Ultra-Sonography (EUS)
  • Magnetic Resonance Imaging (MRI)
  • CT Scanning

Global Exocrine Pancreatic Insufficiency Market, by Geography

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Rest of LATAM
  • Rest of the World
    • South Africa
    • Russia
    • Rest of RoW

Table of Contents

1. Preface

  • 1.1. Report Description
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Assumptions

2. Executive Summary

  • 2.1. Market Snapshot: Exocrine Pancreatic Insufficiency, 2014 & 2023
  • 2.2. Comparative Analysis: Exocrine Pancreatic Insufficiency Market, by Geography (%), 2014 & 2023
  • 2.3. U.S. Exocrine Pancreatic Insufficiency Market, by Type, 2014 (US$ Mn)

3. Exocrine Pancreatic Insufficiency Market - Industry Analysis

  • 3.1. Introduction and Market Definition
  • 3.2. Treatment other than Drug therapy
  • 3.3. Market Dynamics
  • 3.4. Market Attractiveness Analysis of Global Exocrine Pancreatic Insufficiency Market, by Geography
  • 3.5. Impact Analysis
  • 3.6. Pipeline Analysis (Phase II and I) Tabular Presentation
  • 3.7. Competitive Analysis

4. Global Exocrine Pancreatic Insufficiency Market- By Therapeutics 2013-2023 (US$ Mn)

  • 4.1. Overview
  • 4.2. Pancreatic Enzyme Replacement Therapy (PERT) Drugs
    • 4.2.1. Creon
    • 4.2.2. Zenpep
    • 4.2.3. Pancreaze
    • 4.2.4. Ultresa
    • 4.2.5. Viokace
    • 4.2.6. Pertzye
  • 4.3. Exocrine Pancreatic Insufficiency Drugs, Pipeline Analysis, Post launch - 2023, Sollpura (Liprotamase)

5. Global Exocrine Pancreatic Insufficiency Market - By Diagnostic Tests

  • 5.1. Overview
  • 5.2. Blood Tests
  • 5.3. Endoscopic Ultra-Sonography (EUS)
  • 5.4. Magnetic Resonance Imaging (MRI)
  • 5.5. CT Scanning

6. Global Exocrine Pancreatic Insufficiency Market - By Geography

  • 6.1. North America
    • 6.1.1. U.S.
    • 6.1.2. Canada
    • 6.1.3. Rest of North America
  • 6.2. Europe
    • 6.2.1. U.K.
    • 6.2.2. Germany
    • 6.2.3. Rest of Europe
  • 6.3. Asia Pacific
    • 6.3.1. China
    • 6.3.2. Japan
    • 6.3.3. Rest of APAC
  • 6.4. Latin America
    • 6.4.1. Brazil
    • 6.4.2. Mexico
    • 6.4.3. Rest of LATAM
  • 6.5. Rest of the World
    • 6.5.1. South Africa
    • 6.5.2. Russia
    • 6.5.3. Rest of RoW

7. Company Profiles

  • 7.1. Abbvie Inc.
  • 7.2. Allergan plc.
  • 7.3. Nordmark Arzneimittel GmbH & Co. KG
  • 7.4. Digestive Care, Inc.
  • 7.5. Cilian AG
  • 7.6. Anthera Pharmaceuticals Inc.
  • 7.7. Janssen Pharmaceuticals Inc.
  • 7.8. AzurRx BioPharma, Inc.

List of Figures

  • FIG. 1 Market Segmentation
  • FIG. 2 Global Exocrine Pancreatic Insufficiency (EPI) Market Share, by Geography, 2014
  • FIG. 3 Global Exocrine Pancreatic Insufficiency (EPI) Market Share, by Geography, 2023
  • FIG. 4 Exocrine Pancreatic Insufficiency (EPI) Market, by Type, 2014 (US$ Mn)
  • FIG. 5 Global Exocrine Pancreatic Insufficiency Market, by Geography, Value (%), 2014
  • FIG. 6 U.S. Exocrine Pancreatic Insufficiency Market, by Key Players, 2014 (%)
  • FIG. 7 U.S. Creon Market Revenue, (US$ Mn), 2013-2023
  • FIG. 8 U.S. Zenpep Market Revenue, (US$ Mn), 2013-2023
  • FIG. 9 U.S. Pancreaze Market Revenue, (US$ Mn), 2013-2023
  • FIG. 10 U.S. Ultresa Market Revenue, (US$ Mn), 2013-2023
  • FIG. 11 U.S. Viokace Market Revenue, (US$ Mn), 2013-2023
  • FIG. 12 U.S Pertzye Market Revenue, (US$ Mn), 2013-2023
  • FIG. 13 U.S Sollpura (Liprotamase) Market Revenue, (US$ Mn), 2013-2023
  • FIG. 14 Global Blood Tests Market Revenue, (US$ Mn), 2013-2023
  • FIG. 15 Global Endoscopic ultra-sonography (EUS) Market Revenue, (US$ Mn), 2013-2023
  • FIG. 16 Global Magnetic resonance imaging (MRI) Market Revenue, (US$ Mn), 2013-2023
  • FIG. 17 Global CT scanning Market Revenue, (US$ Mn), 2013-2023
  • FIG. 18 AbbVie, Inc., Annual Revenue, 2013-2015 (US$ Mn)
  • FIG. 19 Allergan plc Annual Revenue, 2012-2014 (US$ Mn)

List of Tables

  • TABLE 1 Exocrine Pancreatic Insufficiency (EPI): Market Snapshot
  • TABLE 2 Impact Analysis
  • TABLE 3 Pipeline Analysis (Phase I and II): Tabular Presentation
  • TABLE 4 U.S. Exocrine Pancreatic Insufficiency (EPI) Market Revenue, (US$ Mn), 2013-2023
  • TABLE 5 Global Exocrine Pancreatic Insufficiency Market Revenue, by Diagnostic Test, (US$ Mn), 2013-2023
  • TABLE 6 Global Exocrine Pancreatic Insufficiency Market Revenue, by Geography, 2013-2023
  • TABLE 7 North America Exocrine Pancreatic Insufficiency Market Revenue, by Country, 2013-2023
  • TABLE 8 Europe Exocrine Pancreatic Insufficiency Market Revenue, by Country, 2013-2023
  • TABLE 9 Asia Pacific Exocrine Pancreatic Insufficiency Market Revenue, by Country, 2013-2023
  • TABLE 10 Latin America Exocrine Pancreatic Insufficiency Market Revenue, by Country, 2013-2023
  • TABLE 11 Rest of the World (RoW) Exocrine Pancreatic Insufficiency Market Revenue, by Country, 2013-2023
Back to Top